



VRL/SEC/EXCHANGE

17.10.2019

National Stock Exchange of India Ltd.
5th Floor, Exchange Plaza
Bandra (E),
Mumbai- 400 051
Script Code: VENUSREM

Dept. of Corporate Services
The Stock Exchange, Mumbai
25th Floor, Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai
Script Code: 526953


Sub: Announcement under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Dear Sir/Madam,

Please find enclosed herewith an announcement under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Thanking you.

Yours faithfully,
for VENUS REMEDIES LIMITED


(Company Secretary)

VENUS REMEDIES LIMITED

Corporate Office :
51-52, Industrial Area, Phase- I, Panchkula (Hry.) 134113, India
Regd. Office :
SCO 857, Cabin No. 10, 2nd Floor, NAC, Manimajra,
Chandigarh (U.T.) 160101, India
Website : www.venusremedies.com
www.vmrindia.com
email : info@venusremedies.com
CIN No. : L24232CH1989PLC009705

Unit-I :
51-52, Industrial Area, Phase-I, Panchkula (Hry.) 134113, India
Tel. : +91-172-3933094, 3933090, 2565577, Fax : +91-172-2565566

Unit-II :
Hill Top Industrial Estate, Jharmajri EPIP, Phase-I, (Extn.),
Bhatoli Kalan, Baddi (H.P.) 173205, India
Tel. : +91-1795-302100, 302101, 302107, Fax : +91-1795-271272

Unit-V :
VENUS PHARMA GmbH
AM Bahnhof 1-3, D-59368, Werne, Germany



Venus announces deal with Cipla for its patented product Elores for Indian Territory

- To ensure greater patient access of Elores in India.
- To strengthen Elores position globally.

Panchkula, India; October 17, 2019: Venus Remedies Limited (BSE: 526953; NSE: VENUSREM) hereafter referred to as ("VRL") announces sale of its patented product Elores to Cipla Limited ("Cipla") for the Indian Territory. This association with Cipla will enable greater patient access of Elores in India.

Elores is a novel combination of Ceftriaxone, Sulbactam and Disodium EDTA indicated for the treatment of life-threatening infections caused by gram-negative bacteria. It preserves the efficacy of the antibiotic using appropriate Antibiotic Resistance Breakers (ARBs). Elores was launched by VRL in India across select tertiary care hospitals in 2013 after approval from the Drug Controller General of India.

The present deal with Cipla for Indian territory will enable VRL to focus its efforts on strengthening its global position for Elores. The global demand for critical care antibiotics has grown significantly over the past two decades. Currently, Elores is available in 7 countries and is scheduled to be launched in another 4 territories over the next 12 months; it is under registration in many other parts of world.

If AMR continues to grow at the present rate, the estimated number deaths is likely to touch 10 million worldwide by 2050.

VRL is spearheading the drive against Antimicrobial resistance (AMR) since 2002 and developing new solutions to address this largely overlooked, global threat to life and livelihood. VRL is committed to antibiotic stewardship through its campaign – plea (preserving life of existing antibiotics). Each year, plea volunteers reaches out to more than 50,000 healthcare professionals and spread awareness on the judicious use of antibiotics and maintaining a sanitary hospital ecology. Plea's innovative social media campaigns collectively reached out to over 1 million people globally in 2018. VRL is also signatory to





US Center for Disease Control and Preventions' (CDC) "Global AMR Challenge" initiative and has committed to antibiotic research and stewardship.

Saransh Chaudhary, CEO, Venus Medicine Research Centre, said: "VRL has been leading the research on novel anti-infectives in India. We've always viewed antimicrobial resistance as a huge public health crisis that needs to be dealt with immediately and at all levels of the healthcare setup. Elores was our response to the problem and it has been very satisfying to see the difference that it has made in the lives of patients. I'm positive that Cipla will expand the reach of Elores to many more patients in India while ensuring a similar commitment to antimicrobial stewardship. AMR continues to be the core focus for us going forward and we hope that our consistent efforts in this space will lead to better outcomes for patients dealing with life-threatening infections."

Umang Vohra, Managing Director and Global Chief Executive Officer, Cipla, said: "Cipla has consistently been at the forefront of promoting rational and judicious use of antibiotics, and has been a leading industry voice in the fight against AMR. Elores underscores our commitment to anti-microbial stewardship and is a significant addition to our branded portfolio of anti-infectives in India. We recently acquired ZEMDRI™, and with the acquisition of Elores, we have added to our offering of new generation antibiotics. In keeping with our purpose of Caring for Life, Elores will improve patient access to innovative quality medicines and help patients battle life-threatening resistance at critical junctures."

About Elores

Elores is a novel combination of Ceftriaxone (third generation beta-lactam cephalosporin), Sulbactam (beta-lactamase inhibitor) and Disodium EDTA (an Antibiotic Resistance Breaker), and it restores the in vitro activity of ceftriaxone against ESBL/MBL producing gram-negative bacteria, including enzyme families that belong to Ambler class A (TEM, SHV, CTX-M), class B (NDM, VIM, IMP), class C (some variants of AmpC), and class D (OXA ESBLs). In the recent concluded Phase-3 clinical trial, Elores was proven to be non-inferior to Meropenem for the treatment of patients suffering from complicated urinary tract infections, including acute pyelonephritis.





About Venus Remedies Limited (VRL):

Established in 1989 in Panchkula, India, Venus Remedies Limited is a research based pharmaceutical company and is among the leading global injectable manufacturers, possessing a wide product basket catering to high-growth therapeutic segments of antimicrobial resistance, oncology, skin & wound care and pain management, with an expansive global footprint extending over 60 nations. VRL has a rich portfolio of both research and generic products with more than 100 patent grants and 600+ marketing authorizations worldwide. The VRL's manufacturing units are accredited with many national and international certifications for Good Manufacturing Practices (GMPs) such as European GMP, Australian GMP, Saudi Arabia, Thailand and from many other leading global regulatory authorities. Besides, Venus Medicine Research Centre, a DSIR-approved, GLP-accredited, state-of-the-art research center, is committed to bring to the world novel breakthroughs that cater to critical care and super specialty segments. Patients are at the core of our thinking and we make sure that our efforts do not end with developing a new product or therapy, but extend beyond to provide a holistic solution to the patients.

About Cipla:

Established in 1935, Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in home markets of India, South Africa, North America, and key regulated and emerging markets. Cipla's strengths in the respiratory, anti-retroviral, urology, cardiology, anti-infective and CNS segments are well-known. Cipla's 46 manufacturing sites around the world produce 50+ dosage forms and 1,500+ products using cutting-edge technology platforms to cater to 80+ markets. Cipla is ranked 3rd largest in pharma in India (IQVIA MAT June'19) and is the 3rd largest in the pharma private market in South Africa (IQVIA MAT June'19). For over eight decades, making a difference to patients has inspired every aspect of Cipla's work. Cipla's paradigm-changing offer of a triple anti-retroviral therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 is widely acknowledged as having contributed to bringing inclusiveness, accessibility and affordability to the centre of the HIV movement. A responsible corporate citizen, Cipla's humanitarian approach to healthcare in pursuit of its purpose of 'Caring for Life' and deep-rooted community links wherever it is present make it a partner of choice to global health bodies, peers and all stakeholders.

